Lengthy negotiations ended in good news recently when the price of rifapentine, a lifesaving antibiotic, was marked down by 66% by its manufacturer Sanofi. When combined with another antibiotic (isoniazid), rifapentine can prevent tuberculosis (TB) disease. The move was announced at the Union World Conference on Lung Health in October 2019.
